| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2006.03.051 |
| P698 | PubMed publication ID | 16714056 |
| P50 | author | Jae Huh | Q58831429 |
| P2093 | author name string | Sonoda Y | |
| Lang J | |||
| Haddad L | |||
| Chi DS | |||
| Abu-Rustum NR | |||
| Levine DA | |||
| Barakat RR | |||
| Hensley M | |||
| Eisenhauer EL | |||
| P2860 | cites work | Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial | Q61900008 |
| Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience | Q67989907 | ||
| A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study | Q68864354 | ||
| The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma | Q72382597 | ||
| The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer | Q72644277 | ||
| The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery | Q72801655 | ||
| Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study | Q73739424 | ||
| Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? | Q73876538 | ||
| Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings | Q77900251 | ||
| Secondary surgical cytoreduction for advanced ovarian carcinoma | Q81123672 | ||
| Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial | Q81545779 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Cancer statistics, 2005 | Q29617572 | ||
| Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator | Q30729206 | ||
| Ablation of metastatic ovarian carcinoma with the argon beam coagulator: pathologic analysis of tumor destruction | Q30729272 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis | Q33957687 | ||
| The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study | Q35611986 | ||
| Epithelial ovarian carcinoma: principles of primary surgery | Q40579768 | ||
| Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? | Q44850890 | ||
| Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study | Q46415035 | ||
| Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach | Q50160858 | ||
| Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. | Q52881651 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian carcinoma | Q18556145 |
| P304 | page(s) | 559-564 | |
| P577 | publication date | 2006-05-22 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? | |
| P478 | volume | 103 |
| Q90663036 | 30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival |
| Q79907097 | A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancers |
| Q90708882 | A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer |
| Q83052427 | A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma |
| Q35926352 | A framework for a personalized surgical approach to ovarian cancer |
| Q40331453 | A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer |
| Q35294575 | A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer |
| Q97691119 | A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer |
| Q44223057 | A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer |
| Q57164774 | A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study |
| Q45014116 | Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? |
| Q37017000 | Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer |
| Q54047420 | Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. |
| Q27852053 | Advanced ovarian cancer: what should be the standard of care? |
| Q40025780 | Aggressive and complex surgery for advanced ovarian cancer: an economic analysis |
| Q84943384 | An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) |
| Q37466140 | Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer |
| Q30485286 | Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project |
| Q34155131 | Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer |
| Q38617648 | Associations between residual disease and survival in epithelial ovarian cancer by histologic type |
| Q53189566 | BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. |
| Q37629308 | Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer |
| Q39478486 | Bladder function after modified posterior exenteration for primary gynecological cancer |
| Q97528626 | Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study |
| Q91043335 | CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy |
| Q51828792 | Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer? |
| Q79926041 | Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis |
| Q91946612 | Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery |
| Q37625835 | Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel |
| Q36758685 | Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management |
| Q27024235 | Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer |
| Q36205609 | Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients |
| Q37286461 | Colon resection for ovarian cancer: intraoperative decisions |
| Q33774527 | Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer |
| Q35793038 | Comparative effectiveness research in gynecologic oncology |
| Q37468209 | Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer |
| Q37092776 | Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. |
| Q58119464 | Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer |
| Q91045719 | Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival? |
| Q53078546 | Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. |
| Q89056087 | Correlation of Pattern of Spread and Outcomes in Advanced Epithelial Ovarian Cancers |
| Q82761568 | Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer |
| Q42655076 | Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. |
| Q50213512 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience |
| Q38193876 | Cytoreductive surgery for advanced ovarian cancer |
| Q58766386 | Cytoreductive surgery in primary advanced epithelial ovarian cancer |
| Q61787748 | Debulking Surgery: Interval Debulking Surgery Versus Primary: Pros and Cons on How to Evaluate Quality |
| Q34281226 | Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes |
| Q85014716 | Defining the limits of radical cytoreductive surgery for ovarian cancer |
| Q38442672 | Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer |
| Q33644637 | Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma |
| Q37433018 | Diaphragmatic peritonectomy versus full thickness diaphragmatic resection and pleurectomy during cytoreduction in patients with ovarian cancer |
| Q37642976 | Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer. |
| Q33690432 | Diffusion-weighted Imaging of Peritoneal Disease for Noninvasive Staging of Advanced Ovarian Cancer |
| Q30360249 | Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 |
| Q36125424 | Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients |
| Q43204758 | Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? |
| Q38076257 | Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative |
| Q88440462 | Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm |
| Q38980176 | Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible |
| Q36850922 | En bloc pelvic resection for advanced ovarian cancer preceded by central ligation of vessels supplying the tumor bed: a description of surgical technique and a feasibility study |
| Q38007750 | Evaluation of Society of Gynecologic Oncologists (SGO) ovarian cancer quality surgical measures. |
| Q37988243 | Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. |
| Q61452291 | Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer |
| Q33605208 | Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study |
| Q92862978 | Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer |
| Q47803626 | Gene expression meta-analysis identifies chromosomal regions involved in ovarian cancer survival |
| Q86457326 | Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery |
| Q42660155 | Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer |
| Q43114850 | Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role? |
| Q85174042 | Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment |
| Q47848645 | Image-guided surgery in gynecologic oncology |
| Q48709352 | Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors |
| Q37729815 | Imaging ovarian cancer and peritoneal metastases--current and emerging techniques |
| Q38807470 | Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis |
| Q38372474 | Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. |
| Q36796557 | Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. |
| Q30486797 | Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model |
| Q83733281 | Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm |
| Q37428269 | In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon |
| Q90418977 | In response to: Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis |
| Q36216787 | Incidental events of diaphragmatic surgery in 82 patients with advanced ovarian, primary peritoneal and fallopian tubal cancer |
| Q36474863 | Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer |
| Q37161861 | Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas |
| Q37369523 | Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer |
| Q44781487 | Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer |
| Q51174141 | Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. |
| Q44664182 | Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? |
| Q57212815 | It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer |
| Q37988903 | Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum). |
| Q80421493 | Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer |
| Q49399386 | Long non-coding RNA SOX2OT promotes cell proliferation and motility in human ovarian cancer |
| Q36251477 | Lymphocele and ovarian cancer: risk factors and impact on survival |
| Q34517694 | Major clinical research advances in gynecologic cancer in 2010 |
| Q36965471 | Management of complex pelvic masses using a multivariate index assay: a decision analysis |
| Q33955721 | Maximal cytoreductive effort in epithelial ovarian cancer surgery |
| Q88015812 | Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer |
| Q35906242 | Metastatic disease to the breast: the Washington University experience |
| Q55638402 | Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer |
| Q89203988 | Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? |
| Q36109709 | Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. |
| Q53340667 | Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. |
| Q48858978 | Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. |
| Q38499574 | Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. |
| Q37909365 | Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions |
| Q45298388 | Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? |
| Q85016197 | Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists? |
| Q34389383 | Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy |
| Q35552391 | Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer |
| Q83534840 | New terminology for cytoreduction in advanced ovarian cancer |
| Q86108427 | Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients |
| Q53029146 | Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. |
| Q80232806 | Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer |
| Q36996789 | Operative management of primary epithelial ovarian cancer |
| Q86789064 | Optimal (≤1 cm) but visible residual disease: is extensive debulking warranted? |
| Q39855224 | Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group |
| Q38941559 | Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? |
| Q24234923 | Optimal primary surgical treatment for advanced epithelial ovarian cancer |
| Q44579894 | Optimizing management tools for ovarian cancer improves survival |
| Q40442544 | Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection |
| Q90412906 | Outcome of Bowel Resection in Women with Advanced Ovarian Carcinoma |
| Q53408126 | Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. |
| Q37540704 | Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma |
| Q38703668 | Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter |
| Q38528010 | Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature |
| Q92901866 | Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer |
| Q36811358 | Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy |
| Q37356298 | Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass |
| Q39059860 | Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer. |
| Q37842973 | Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review. |
| Q55174606 | Positive Surgical Margins in the 10 Most Common Solid Cancers. |
| Q102070617 | Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer |
| Q35919110 | Preclinical evaluation of Mab CC188 for ovarian cancer imaging |
| Q40274564 | Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography |
| Q46869580 | Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study |
| Q46325180 | Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study |
| Q64935931 | Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis. |
| Q91744535 | Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study |
| Q35758709 | Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer |
| Q92524306 | Preoperative colonoscopy in patients with a supposed primary ovarian cancer |
| Q51628545 | Preoperative prediction of suboptimal resection in advanced ovarian cancer based on clinical and CT parameters. |
| Q94586088 | Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
| Q38260301 | Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? |
| Q26851149 | Primary metastatic breast cancer: the impact of locoregional therapy |
| Q37937935 | Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer |
| Q37685630 | Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer |
| Q91827282 | Prognostic SIGNIFICANCE of Cytoreductive Therapy of Ovarian Cancer - eastern Croatia experience |
| Q80070150 | Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A |
| Q30359038 | Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. |
| Q48211376 | Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer |
| Q45971170 | Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. |
| Q35818203 | Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. |
| Q48794449 | Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre |
| Q36689828 | Quality of life for patients with epithelial ovarian cancer |
| Q38661788 | Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study |
| Q35581020 | Racial disparities and patterns of ovarian cancer surgical care in California |
| Q38364615 | Radical surgery in ovarian cancer |
| Q35744585 | Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. |
| Q88601013 | Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months |
| Q39221812 | Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an α(v)β(3-)integrin targeted agent |
| Q37861289 | Recent surgical management of ovarian cancer |
| Q38007298 | Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. |
| Q39085518 | Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma |
| Q48248709 | Relevance of enlarged cardiophrenic lymph nodes in determining prognosis of patients with advanced ovarian cancer |
| Q36628904 | Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer |
| Q35748533 | Risk stratification and outcomes of women undergoing surgery for ovarian cancer |
| Q37729033 | Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer |
| Q26801358 | Role of aggressive surgical cytoreduction in advanced ovarian cancer |
| Q92618045 | Role of laparoscopy in initial tumour staging in advanced epithelial ovarian cancer: A systematic review |
| Q83287534 | Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial |
| Q36573447 | Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers |
| Q51800854 | Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. |
| Q26771731 | Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients |
| Q92125121 | Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease? |
| Q87123589 | Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility |
| Q38424916 | Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): a questionnaire survey |
| Q91713471 | Survival Analysis of Lymph Node Resection in Ovarian Cancer: A Population-Based Study |
| Q51809291 | Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study. |
| Q34762831 | Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis |
| Q37036784 | Survivorship as an element of clinical trials in ovarian cancer |
| Q37182292 | TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer |
| Q36979097 | Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore |
| Q37699802 | Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series |
| Q80155214 | The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer |
| Q36830674 | The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum |
| Q81586923 | The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer |
| Q30418957 | The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study |
| Q51069760 | The impact of total parenteral nutrition on postoperative recovery in patients treated for advanced stage ovarian cancer. |
| Q39084944 | The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer. |
| Q50168618 | The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas |
| Q80074520 | The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking |
| Q40443819 | The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer |
| Q92071749 | The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review |
| Q37938361 | The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma |
| Q37832930 | The role of surgery in the management of epithelial ovarian cancer |
| Q44109589 | Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. |
| Q51817178 | Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. |
| Q92487316 | Tozzi classification of diaphragmatic surgery in patients with stage IIIC-IV ovarian cancer based on surgical findings and complexity |
| Q39405578 | Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. |
| Q97874907 | Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population |
| Q44621833 | Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. |
| Q33816983 | Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer |
| Q47755856 | Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022). |
| Q88087857 | Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy |
| Q84185686 | Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer |
| Q45194081 | Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients |
| Q98463162 | Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study |
| Q37397877 | When should surgical cytoreduction in advanced ovarian cancer take place? |
| Q46521949 | Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. |
| Q55663308 | Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. |
| Q58767748 | YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer |
Search more.